Home » Stocks » ZYNE

Zynerba Pharmaceuticals, Inc. (ZYNE)

Stock Price: $4.50 USD 0.04 (0.78%)
Updated Feb 26, 2021 3:59 PM EST - Market closed
After-hours: $4.49 -0.01 (-0.11%) Feb 26, 4:57 PM
Market Cap 134.54M
Revenue (ttm) 86,000
Net Income (ttm) -52.43M
Shares Out 29.24M
EPS (ttm) -2.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $4.50
Previous Close $4.46
Change ($) 0.04
Change (%) 0.78%
Day's Open 4.49
Day's Range 4.29 - 4.74
Day's Volume 1,565,357
52-Week Range 2.55 - 9.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
InvestorPlace - 2 weeks ago

ZYNE stock is on a roll, with investors betting its transdermal therapeutic cannabidiol gel will take off soon. The post ZYNE Stock: Why Zynerba Pharmaceutical Shares Are Soaring Today appeare...

GlobeNewsWire - 1 month ago

DEVON, Pa., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and ne...

GlobeNewsWire - 2 months ago

- Single Trial to be Conducted in Patients with Fragile X Syndrome to Confirm Positive Results Seen in the Population of Responders in the CONNECT-FX Trial -

Business Wire - 2 months ago

DENVER--(BUSINESS WIRE)--Shuman, Glenn & Stecker Investigates Zynerba Pharmaceuticals, Inc. (ZYNE)

Business Wire - 2 months ago

LOS ANGELES--(BUSINESS WIRE)---- $ZYNE #classaction--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Zynerba Pharmaceuticals (“Zynerba” or ...

GlobeNewsWire - 2 months ago

- New Efficacy Data Describe Strong Evidence of Seizure Reduction over 12 Months of Treatment, Including a 73% Median Reduction from Baseline in Monthly Seizure Frequency at Month 12 -

GlobeNewsWire - 3 months ago

DEVON, Pa., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and nea...

Schaeffers Research - 3 months ago

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and we will look ahead at the pot stocks to w...

Other stocks mentioned: ACB, ARNA, CGC, HEXO, HUGE, KERN, OGI, SNDL, TLRY, VFF, YCBD
Benzinga - 3 months ago

Aurora Cannabis Inc. (NYSE:ACB) (TSX:ACB) consolidated net revenue of CA$67.8 million ($52.3 million) for the first quarter of fiscal 2021, being up by around CA$300,000 from the fourth quarte...

Other stocks mentioned: CGC, CNPOF
GlobeNewsWire - 3 months ago

DEVON, Pa., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and nea...

Seeking Alpha - 3 months ago

Zynerba failed a phase 3 study using Zygel to treat the entire Fragile X syndrome population. However, the path forward remains targeting those with methylation of the FMR1 gene. An FDA meetin...

GlobeNewsWire - 4 months ago

DEVON, Pa., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and nea...

GlobeNewsWire - 4 months ago

DEVON, Pa., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and nea...

GlobeNewsWire - 4 months ago

DEVON, Pa., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and nea...

GlobeNewsWire - 4 months ago

DEVON, Pa., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and nea...

Seeking Alpha - 5 months ago

Pivotal results from Phase 3 clinical trials of Zygel for the treatment of FX Syndrome didn’t meet endpoints, but a significant discovery was made.

Zacks Investment Research - 5 months ago

Zynerba Pharmaceuticals (ZYNE) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Seeking Alpha - 5 months ago

Making The Case For Zynerba Pharmaceuticals

GlobeNewsWire - 5 months ago

DEVON, Pa., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and ...

GlobeNewsWire - 5 months ago

- Meeting with the U.S. Food and Drug Administration (FDA) Planned for 4Q2020 to Discuss the Regulatory Path Forward for Zygel™ in Children and Adolescents with Fragile X Syndrome and a Fully ...

GlobeNewsWire - 5 months ago

DEVON, Pa., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and ...

Seeking Alpha - 6 months ago

Exploring more about medical/pharma side of cannabis sector and thematic ETF investing.

Other stocks mentioned: ACT, ARNA, CNBS, CWBHF, GRWG, GWPH, IIPR, MJ, POTX, SMG, THCX, TOKE, YOLO
GlobeNewsWire - 6 months ago

DEVON, Pa., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and n...

GlobeNewsWire - 6 months ago

DEVON, Pa., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and n...

Seeking Alpha - 6 months ago

Pharma Medical Cannabis More Robust And Resilient (Podcast)

Other stocks mentioned: ACT, ARNA, CNBS, CWBHF, GRWG, GWPH, IIPR, MJ, POTX, SMG, THCX, TOKE, YOLO
Zacks Investment Research - 6 months ago

Zynerba Pharmaceuticals (ZYNE) closed the most recent trading day at $3.79, moving +1.34% from the previous trading session.

Zacks Investment Research - 7 months ago

Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to have increased in the second quarter due to clinical studies on its lead pipeline candidate, Zygel.

GlobeNewsWire - 7 months ago

- New Data Show Statistically Significant Improvements in Caregiver Impression of Change in Fragile X Behaviors Including Social Avoidance in Patients with Fully Methylated FMR1 genes - - New ...

Seeking Alpha - 7 months ago

Iveric's Trial Progress And Other News: The Good, Bad And Ugly Of Biopharma

Other stocks mentioned: ISEE, RUBY
Zacks Investment Research - 7 months ago

Zynerba's (ZYNE) shares plunge 48.5% following the study data readout, which demonstrated failure to achieve statistical significance in primary endpoint.

Benzinga - 7 months ago

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) shares retreated to their lowest level since early April following a clinical readout from the company.

24/7 Wall Street - 7 months ago

Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) has disclosed that its cannabis-based gel did not see statistically significant results from its most recent study.

GlobeNewsWire - 7 months ago

- Study Did Not Achieve Statistical Significance in Primary or Key Secondary Endpoints in Full Analysis Set -

Zacks Investment Research - 7 months ago

Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.

Zacks Investment Research - 8 months ago

The marijuana stocks plunged during the coronavirus sell-off. Should investors be taking a second look?

Other stocks mentioned: ACB, CGC, GWPH, HEXO
24/7 Wall Street - 8 months ago

The 2020 year is practically halfway done, and this has really been the year of the biotech.

Other stocks mentioned: ACAD, BIIB, BTAI, CRTX, ITCI, NBIX, SAGE
24/7 Wall Street - 8 months ago

The stock market’s fall from February through March was monumental, bringing on the fastest bear market we have seen in our lives.

Other stocks mentioned: AXLA, FLY, FMCC, FNMA, GLOG, GPP, PGEN, SNCR
GlobeNewsWire - 8 months ago

- The BRIGHT Trial Achieved Statistically Significant and Clinically Meaningful Improvements from Baseline in All Subscales of the Aberrant Behavior Checklist -

GlobeNewsWire - 9 months ago

- Robust Response Sustained through Two Years of Treatment with Zygel™ in Patients from Phase 2 FAB-C Trial -

GlobeNewsWire - 9 months ago

DEVON, Pa., May 26, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and ne...

Zacks Investment Research - 9 months ago

Is (ZYNE) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 10 months ago

Zynerba Pharmaceuticals (ZYNE) closed the most recent trading day at $3.47, moving +1.76% from the previous trading session.

GlobeNewsWire - 11 months ago

- New Data Presented Today at the American Society for Experimental Neurotherapeutics (ASENT) 2020 Meeting - - New Data Presented Today at the American Society for Experimental Neurotherapeuti...

Zacks Investment Research - 11 months ago

Zynerba Pharmaceuticals (ZYNE) closed at $4.18 in the latest trading session, marking a -1.88% move from the prior day.

GlobeNewsWire - 1 year ago

Topline Results are expected late in the Second Quarter of 2020 Topline Results are expected late in the Second Quarter of 2020

GlobeNewsWire - 1 year ago

DEVON, Pa., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and n...

Zacks Investment Research - 1 year ago

Zynerba Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

GlobeNewsWire - 1 year ago

- Company Expects to Complete Randomization in February 2020 -

Investopedia - 1 year ago

The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges.

Other stocks mentioned: ARNA, CARA, CRBP, CRON, GNLN, GWPH, MBII, NBEV, NTEC, OGI, PMD, SNDL, TLRY, TRPX, VFF
Zacks Investment Research - 1 year ago

In the latest trading session, Zynerba Pharmaceuticals (ZYNE) closed at $5.70, marking a -0.35% move from the previous day.

About ZYNE

Zynerba Pharmaceuticals operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental and epileptic encephalopathies; is in Phase II clinical trial for treating children and adolescent patients with autism spectrum disorder; is in Phase II clinical... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Aug 5, 2015
CEO
Armando Anido
Employees
28
Stock Exchange
NASDAQ
Ticker Symbol
ZYNE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for ZYNE stock is "Buy." The 12-month stock price forecast is 7.25, which is an increase of 61.29% from the latest price.

Price Target
$7.25
(61.29% upside)
Analyst Consensus: Buy